Still in spotlight of a federal probe, Insys touts PhIII pain study as it preps an NDA
Still in the spotlight for federal investigations surrounding several cases of off-label marketing, Insys Therapeutics $INSY says it has come up with promising Phase III data for its most advanced spray formulation of an aging drug.
The drug is Buprenorphine Sublingual Spray, a new formulation for an addiction drug that is being repurposed to treat pain. Phoenix-based Insys says that they hit the primary endpoint in the study, testing three doses against a placebo for moderate to severe postoperative pain after a “bunionectomy.” The statement did not include any data, though. Now the company wants to start moving toward a new drug application.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.